Our current partners:
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. Napp believe in excellence and delivering on our promises to the NHS, patients, our business partners and each other. Napp strive to offer new medicines and initiatives that meet genuine needs, make a positive difference to patients’ lives and support the NHS in delivering effective, high-quality, sustainable healthcare.
Orion is a Finnish-born, innovative European R&D-based pharmaceuticals and diagnostics company with an emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients as well as diagnostic tests. Orion carries out extensive research with a goal of introducing new treatments into global markets. The core therapy areas in Orion’s product and research strategy are the central nervous system, oncology, critical care and respiratory medicines.
Our partnership with Vax provides us with a platform to communicate key health advice messages directly to people with asthma. The partnership will ensure that people who purchase Vax air purifiers are given advice and support on steps they can take to reduce the impact of harmful triggers and prevent life-threatening asthma attacks.
From May 2021, Irwin Mitchell will be supporting our work with the aim of boosting the support services available to people living with lung disease across the four nations. The partnership, will help us to continue providing support to the 6.5 million people living with a lung condition and their families. This will include helping our network of 155 volunteer-led support groups across England, Northern Ireland, Scotland and Wales get back up and running again once the COVID-19 restrictions have lifted.